To the Editor:rnMore recently, the ongoing dissemination of the novel coronavirus disease 2019 (COVID-19) is posing an unprecedented threat to global healthcare systems1,2.Since the outbreak, COVID-19 has escalated to well over 24,775,000 cases and caused over 837,000 deaths worldwide by August 29, 2020.Angiotensin converting enzyme 2 (ACE2) has garnered widespread interest as the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of COVID-19 pandemic, providing a critical link among COVID-19, inflammatory storm, ACE2 and cardiovascular disease1,2.Thus, this brings controversy and challenge to clinical practice: does increased ACE2 level mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19.